This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
rights reserved | 161 |
coronavirus disease | 105 |
cutaneous manifestations | 89 |
dermatol ther | 86 |
ther doi | 81 |
doc id | 81 |
cord uid | 81 |
novel coronavirus | 53 |
health care | 41 |
atopic dermatitis | 40 |
acute respiratory | 36 |
dermatology outpatient | 35 |
outpatient clinic | 34 |
severe covid | 33 |
like lesions | 32 |
face masks | 31 |
systematic review | 31 |
protective equipment | 30 |
case series | 29 |
personal protective | 29 |
care workers | 28 |
healthcare workers | 27 |
pityriasis rosea | 26 |
respiratory syndrome | 26 |
increased risk | 25 |
dermatology consultations | 25 |
patients treated | 24 |
cutaneous findings | 24 |
skin diseases | 23 |
intensive care | 22 |
severe acute | 22 |
skin lesions | 22 |
general population | 22 |
higher risk | 22 |
outpatient clinics | 21 |
plaque psoriasis | 21 |
years old | 21 |
kawasaki disease | 20 |
pandemic period | 20 |
psoriasis patients | 20 |
psoriatic patients | 20 |
infection risk | 20 |
biologic therapy | 20 |
disseminated intravascular | 19 |
clinical features | 19 |
hidradenitis suppurativa | 19 |
skin manifestations | 18 |
intravascular coagulation | 18 |
pressure sores | 18 |
psoriatic arthritis | 17 |
contact dermatitis | 17 |
cytokine storm | 17 |
respiratory distress | 16 |
surgical masks | 15 |
hand hygiene | 15 |
acute generalized | 15 |
hand eczema | 15 |
critically ill | 15 |
skin rash | 15 |
severe disease | 15 |
exanthematous pustulosis | 15 |
syndrome coronavirus | 15 |
care unit | 15 |
side effects | 15 |
generalized exanthematous | 15 |
social distancing | 14 |
purpura fulminans | 14 |
severe psoriasis | 14 |
first perspective | 14 |
aesthetic clinics | 14 |
world health | 14 |
limit treatment | 14 |
hospitalized patients | 14 |
infection control | 14 |
severe plaque | 13 |
pso patients | 13 |
immune response | 13 |
health organization | 13 |
dermatological diseases | 13 |
herpes zoster | 13 |
cutaneous lesions | 12 |
patients infected | 12 |
pemphigus vulgaris | 12 |
clinical characteristics | 12 |
severe cutaneous | 12 |
surgical smoke | 12 |
distress syndrome | 12 |
corona virus | 12 |
dermatological patients | 12 |
pandemic date | 12 |
covid infection | 12 |
close contact | 12 |
dermatitis artefacta | 12 |
adverse events | 12 |
serious infections | 11 |
two patients | 11 |
case report | 11 |
informed consent | 11 |
high risk | 11 |
drug reactions | 11 |
aerosol box | 11 |
emergency department | 11 |
infected patients | 11 |
viral transmission | 10 |
converting enzyme | 10 |
may also | 10 |
skin cancer | 10 |
generalized pustular | 10 |
dermatology practices | 10 |
lupus erythematosus | 10 |
risk perception | 10 |
dermatologic disease | 10 |
risk factors | 10 |
hand washing | 10 |
mg kg | 10 |
case reports | 10 |
androgen receptor | 10 |
adverse effects | 10 |
cutaneous drug | 10 |
biological treatment | 10 |
cutaneous symptoms | 10 |
wound healing | 10 |
mucous membrane | 10 |
authors declare | 10 |
biologic agents | 10 |
epidermolysis bullosa | 10 |
aesthetic procedures | 10 |
dermatologic surgery | 9 |
erythematous rash | 9 |
urticarial lesions | 9 |
rapid prospective | 9 |
disease control | 9 |
may lead | 9 |
aesthetic clinic | 9 |
mean age | 9 |
one patient | 9 |
cloth masks | 9 |
facemask wearing | 9 |
among healthcare | 9 |
ad patients | 9 |
infectious diseases | 9 |
ill patients | 9 |
clinical trial | 9 |
among health | 9 |
nationwide consensus | 9 |
coronavirus infection | 9 |
statistically significant | 9 |
prospective nationwide | 9 |
skin disease | 9 |
psoriatic patient | 9 |
biological therapy | 9 |
growth factor | 9 |
consensus study | 9 |
phase iii | 8 |
united states | 8 |
mental health | 8 |
toxic epidermal | 8 |
literature review | 8 |
underlying dermatologic | 8 |
dermatological consultations | 8 |
systemic treatment | 8 |
acral cyanosis | 8 |
dermatologic therapy | 8 |
fibroblast growth | 8 |
immune system | 8 |
search terms | 8 |
current pandemic | 8 |
drug reaction | 8 |
significant difference | 8 |
cov infection | 8 |
systemic therapy | 8 |
dermatologic disorders | 8 |
respiratory symptoms | 8 |
epidermal necrolysis | 8 |
covid pandemic | 8 |
viral infections | 7 |
airway inflammation | 7 |
livedo reticularis | 7 |
consensus group | 7 |
pulmonary surfactant | 7 |
topical rh | 7 |
control measures | 7 |
filtering facepiece | 7 |
sars coronavirus | 7 |
pustular figurate | 7 |
frequent hand | 7 |
accepted article | 7 |
acne vulgaris | 7 |
global health | 7 |
laser hair | 7 |
dermatologic diseases | 7 |
hemorrhagic bullae | 7 |
biologics may | 7 |
randomized clinical | 7 |
polymerase chain | 7 |
retrospective study | 7 |
skin damage | 7 |
human herpesvirus | 7 |
surgical mask | 7 |
pemphigus patients | 7 |
monoclonal antibody | 7 |
molecular mimicry | 7 |
disease severity | 7 |
clinical trials | 7 |
verruca vulgaris | 7 |
skin disorders | 7 |
coronavirus pandemic | 7 |
dermatological findings | 7 |
daily practice | 7 |
first case | 7 |
controlled trial | 7 |
chain reaction | 7 |
patients affected | 7 |
biologic therapies | 7 |
clinical practice | 7 |
organ failure | 7 |
face mask | 7 |
workers managing | 7 |
hs patients | 7 |
managing coronavirus | 7 |
case basis | 7 |
related skin | 7 |
sample size | 7 |
cutaneous manifestation | 7 |
systemic lupus | 7 |
figurate erythema | 7 |
public health | 7 |
consensus statement | 7 |
intravenous immunoglobulin | 7 |
internal medicine | 6 |
palpable purpura | 6 |
risk categorization | 6 |
fatality rate | 6 |
occupational skin | 6 |
safety measures | 6 |
cutaneous adverse | 6 |
high levels | 6 |
dhh patients | 6 |
mortality due | 6 |
young people | 6 |
italian guidelines | 6 |
northern italy | 6 |
dermatology staff | 6 |
may occur | 6 |
facepiece respirators | 6 |
dermatology practice | 6 |
randomized controlled | 6 |
global pandemic | 6 |
differential diagnosis | 6 |
higher mortality | 6 |
immunosuppressive drugs | 6 |
systemic symptoms | 6 |
aesthetic practice | 6 |
pooled analysis | 6 |
systemic medications | 6 |
systemic treatments | 6 |
life data | 6 |
among patients | 6 |
specific antibodies | 6 |
staff participate | 6 |
middle east | 6 |
consensus guidelines | 6 |
immunosuppressed patients | 6 |
age groups | 6 |
lockdown period | 6 |
acral cutaneous | 6 |
first time | 6 |
elderly patients | 6 |
face shield | 6 |
three cases | 6 |
patients undergoing | 6 |
acute urticaria | 6 |
dear editor | 6 |
damage among | 6 |
consultations requested | 6 |
infection prevention | 6 |
chronic plaque | 6 |
preliminary study | 6 |
many countries | 6 |
blood tests | 6 |
relative change | 6 |
pityriasis rosae | 6 |
urticarial rashes | 6 |
maculopapular eruption | 6 |
independence test | 6 |
mohamad title | 6 |
old man | 6 |
necrosis factor | 6 |
risk patients | 6 |
significantly higher | 6 |
icu admission | 6 |
erythema multiforme | 6 |
endothelial cells | 6 |
complement associated | 6 |
square independence | 6 |
disease among | 6 |
old woman | 6 |
retrospective analysis | 6 |
confirmed cases | 6 |
female patients | 6 |
repeated applications | 6 |
aerosol generating | 6 |
tumor necrosis | 6 |
ar expression | 6 |
generating procedures | 6 |
associated skin | 6 |
five cases | 6 |
median age | 6 |
covid patients | 6 |
biologic treatment | 6 |
important role | 6 |
maculopapular lesions | 5 |
pressure injury | 5 |
diagnostic distribution | 5 |
respiratory comorbidities | 5 |
two weeks | 5 |
new zealand | 5 |
february nd | 5 |
patients showed | 5 |
isotretinoin treatment | 5 |
acidic fibroblast | 5 |
severe respiratory | 5 |
new contribution | 5 |
positive patients | 5 |
nasopharyngeal swab | 5 |
mild symptoms | 5 |
least weeks | 5 |
nan dear | 5 |
olfactory dysfunction | 5 |
available data | 5 |
confirmed covid | 5 |
associated microvascular | 5 |
dry cough | 5 |
adult patients | 5 |
isotretinoin therapy | 5 |
incubation period | 5 |
like exanthem | 5 |
hair loss | 5 |
coronavirus pneumonia | 5 |
maybe used | 5 |
viral pandemic | 5 |
case fatality | 5 |
skin mucosa | 5 |
mg day | 5 |
safety profile | 5 |
irritant contact | 5 |
psoriasis increase | 5 |
pandemic era | 5 |
insert table | 5 |
infection risks | 5 |
european countries | 5 |
statistically significantly | 5 |
viral infection | 5 |
uncertain times | 5 |
biological drugs | 5 |
useful tool | 5 |
pv patients | 5 |
mucosa diseases | 5 |
cardiovascular disease | 5 |
skin reactions | 5 |
patient counseling | 5 |
chinese experts | 5 |
infected pneumonia | 5 |
nasal mucosa | 5 |
eb patients | 5 |
plastic handle | 5 |
patient treated | 5 |
dress syndrome | 5 |
host cells | 5 |
may increase | 5 |
peripheral gangrene | 5 |
cohort study | 5 |
clinical picture | 5 |
sexually transmitted | 5 |
university hospital | 5 |
pediatric patients | 5 |
performed using | 5 |
significant increase | 5 |
new coronavirus | 5 |
biologics increase | 5 |
viral load | 5 |
disease activity | 5 |
patients taking | 5 |
clinical presentation | 5 |
proinflammatory cytokines | 5 |
general dermatology | 5 |
patients admitted | 5 |
infectious disease | 5 |
patients presented | 5 |
clinical symptoms | 5 |
patients may | 5 |
cutaneous signs | 5 |
achieved pasi | 5 |
clinical course | 5 |
acute acro | 5 |
antiviral drugs | 5 |
preventive measures | 5 |
dermatology clinics | 5 |
microvascular injury | 5 |
vesicular rash | 5 |
alopecia areata | 5 |
part i | 5 |
urticarial eruption | 5 |
recent study | 5 |
androgenetic alopecia | 5 |
one study | 5 |
cell carcinoma | 5 |
pandemic may | 5 |
disease course | 5 |
ethics committee | 5 |
immunosuppressive immunomodulators | 5 |
patients stop | 5 |
maculopapular rash | 5 |
clinical studies | 5 |
tongji hospital | 5 |
two cases | 5 |
operating experience | 5 |
epidemic area | 5 |
dermatology residents | 5 |
face protection | 5 |
will cases | 5 |
inflammatory cytokines | 5 |
bacterial skin | 5 |
may reduce | 4 |
symmetrical peripheral | 4 |
clinic visits | 4 |
systemic inflammation | 4 |
skin changes | 4 |
angiotensin converting | 4 |
young adults | 4 |
igm igg | 4 |
online meeting | 4 |
dermatology group | 4 |
reaction linked | 4 |
san matteo | 4 |
large cohort | 4 |
scoring system | 4 |
pandemic literature | 4 |
lockdown restrictions | 4 |
phase trials | 4 |
treating physician | 4 |
respiratory droplets | 4 |
clinic consultations | 4 |
case details | 4 |
small molecules | 4 |
delineated severe | 4 |
may rd | 4 |
cases covid | 4 |
extended use | 4 |
chronic inflammatory | 4 |
may induce | 4 |
skin fragility | 4 |
rational use | 4 |
dermatological procedures | 4 |
patients also | 4 |
multiple sclerosis | 4 |
mycophenolate mofetil | 4 |
latex gloves | 4 |
disease flare | 4 |
short time | 4 |
autoimmune bullous | 4 |
virus infection | 4 |
current evidence | 4 |
chronic diseases | 4 |
respiratory protection | 4 |
newly delineated | 4 |
every day | 4 |
findings table | 4 |
inclusion criteria | 4 |
healthcare providers | 4 |
hydrogen peroxide | 4 |
like rash | 4 |
mucociliary clearance | 4 |
like skin | 4 |
thrombogenic vasculopathy | 4 |
zealand consensus | 4 |
skin conditions | 4 |
respiratory diseases | 4 |
warming sweating | 4 |
hepatic failure | 4 |
skin biopsy | 4 |
coronavirus dermatology | 4 |
hair removal | 4 |
increased infection | 4 |
low dose | 4 |
using google | 4 |
male patients | 4 |
severe dermatological | 4 |
unfolding conundrum | 4 |
inflammatory skin | 4 |
nottingham university | 4 |
ten days | 4 |
required hospitalization | 4 |
immunosuppressive treatment | 4 |
square tests | 4 |
respiratory disease | 4 |
fight covid | 4 |
wearing masks | 4 |
surfactant production | 4 |
small sample | 4 |
important lessons | 4 |
management strategies | 4 |
many patients | 4 |
two phase | 4 |
data concerning | 4 |
nose bridge | 4 |
may play | 4 |
year old | 4 |
kg daily | 4 |
surface stability | 4 |
vasculopathic lesions | 4 |
febrile rash | 4 |
squamous cell | 4 |
overall infection | 4 |
based hand | 4 |
adverse reactions | 4 |
controlled study | 4 |
infection rate | 4 |
invasive procedures | 4 |
search term | 4 |
outpatient applications | 4 |
care personnel | 4 |
elastomeric respirators | 4 |
hair reduction | 4 |
tissue distribution | 4 |
specific covid | 4 |
health community | 4 |
blistering diseases | 4 |
psoriasis treatment | 4 |
older adults | 4 |
two different | 4 |
hygiene measures | 4 |
google trends | 4 |
antiphospholipid antibodies | 4 |
first study | 4 |
may worsen | 4 |
protective measures | 4 |
written informed | 4 |
rosae patients | 4 |
drug eruptions | 4 |
recent studies | 4 |
chinese center | 4 |
exanthem associated | 4 |
anogenital warts | 4 |
directly related | 4 |
infections among | 4 |
oropharyngeal swab | 4 |
severe pneumonia | 4 |
skin manifestation | 4 |
among general | 4 |
brief review | 4 |
metabolic syndrome | 4 |
dic may | 4 |
topical therapy | 4 |
observational study | 4 |
fixed drug | 4 |
risk factor | 4 |
reserved key | 4 |
membrane barrier | 4 |
lower risk | 4 |
systemic isotretinoin | 4 |
critical covid | 4 |
zone declaration | 4 |
workers fighting | 4 |
dermatology resource | 4 |
severity index | 4 |
surgical plume | 4 |
dermatologic manifestations | 4 |
masks among | 4 |
like symptoms | 4 |
latent tuberculosis | 4 |
generating procedure | 4 |
human coronaviruses | 4 |
concomitant biological | 4 |
skin findings | 4 |
statistical analysis | 4 |
general public | 4 |
blood circulation | 4 |
systemic agents | 4 |
great concern | 4 |
psoriasis psoriatic | 4 |
patients hospitalized | 4 |
age group | 4 |
treatment options | 4 |
rash associated | 4 |
dermatologic manifestation | 4 |
induced pressure | 4 |
malignant melanoma | 4 |
square test | 4 |
humoral immunity | 4 |
healthcare settings | 4 |
spike protein | 4 |
may cause | 4 |
medical history | 4 |
old girl | 4 |
acne patients | 4 |
may benefit | 4 |
sars patients | 4 |
online ahead | 4 |
severe cases | 4 |
ischemic lesions | 4 |
rapidly spread | 4 |
taking rituximab | 4 |
specific treatment | 4 |
infection covid | 4 |
review date | 4 |
task force | 4 |
masks wearing | 4 |
controlled trials | 4 |
first report | 4 |
clinic staff | 4 |
supplement file | 4 |
zhongfaxincheng campus | 4 |
histopathological findings | 4 |
cutaneous disease | 4 |
mucous membranes | 4 |
bullous pemphigoid | 4 |
dermatology department | 4 |
barrier creams | 4 |
petechial lesions | 4 |
first confirmed | 4 |
systemic corticosteroids | 4 |
total number | 4 |
line treatment | 4 |
generalized pruritus | 4 |
higher rate | 4 |
sectional study | 4 |
potential conflict | 4 |
sars cov | 4 |
pregnant women | 4 |
long time | 4 |
urticaria angioedema | 4 |
poorer outcomes | 3 |
ongoing covid | 3 |
urticarial rash | 3 |
ms patients | 3 |
disease increased | 3 |
allergic contact | 3 |
treatment failure | 3 |
abrupt interruption | 3 |
atopic patients | 3 |
low risk | 3 |
nasopharyngeal swabs | 3 |
associated comorbidities | 3 |
zone area | 3 |
eyelid dermatitis | 3 |
pemphigus foliaceus | 3 |
confirmed case | 3 |
medical masks | 3 |
vertical transmission | 3 |
chronic dermatological | 3 |
pediatric dermatology | 3 |
based study | 3 |
four patients | 3 |
make sure | 3 |
increased viral | 3 |
procedure rooms | 3 |
global emergency | 3 |
dermatological ed | 3 |
perspective cutaneous | 3 |
dose reduction | 3 |
drug eruption | 3 |
widespread urticaria | 3 |
outpatient dermatologic | 3 |
cutaneous reactions | 3 |
different settings | 3 |
innate immunity | 3 |
airborne transmission | 3 |
seborrheic keratosis | 3 |
study evaluating | 3 |
cell entry | 3 |
upper respiratory | 3 |
benefit ratio | 3 |
systemic manifestations | 3 |
angiotensin ii | 3 |
respiratory infections | 3 |
sexual dimorphism | 3 |
tertiary care | 3 |
new data | 3 |
main categories | 3 |
increased number | 3 |
china clinical | 3 |
glasses misting | 3 |
da coronavirus | 3 |
google scholar | 3 |
scaly rash | 3 |
diagnostic clue | 3 |
skin wound | 3 |
petechial skin | 3 |
treating pv | 3 |
various studies | 3 |
pivotal trials | 3 |
observational cohort | 3 |
east respiratory | 3 |
bullous disorders | 3 |
staphylococcus aureus | 3 |
care management | 3 |
common skin | 3 |
inflammatory conditions | 3 |
first month | 3 |
patients experienced | 3 |
predisposition wore | 3 |
diagnostic categories | 3 |
hospital automation | 3 |
nasal mucociliary | 3 |
gastrointestinal symptoms | 3 |
use masks | 3 |
serious infection | 3 |
dermatologic journals | 3 |
data sharing | 3 |
human coronavirus | 3 |
infected people | 3 |
multicenter case | 3 |
binding domain | 3 |
stress burden | 3 |
risk procedures | 3 |
increasing number | 3 |
preferred practices | 3 |
chilblains disease | 3 |
dupilumab may | 3 |
advice regarding | 3 |
continued care | 3 |
laboratory tests | 3 |
patients receiving | 3 |
contact time | 3 |
reduces pressure | 3 |
slight predominance | 3 |
aesthetic dermatology | 3 |
idiopathic generalized | 3 |
low rate | 3 |
coronavirus covid | 3 |
normal population | 3 |
prospective study | 3 |
safety precautions | 3 |
skin dermatoses | 3 |
organization declares | 3 |
immune dysregulation | 3 |
dermatological clinic | 3 |
st june | 3 |
various cutaneous | 3 |
life quality | 3 |
logistic regression | 3 |
immunosuppressive therapies | 3 |
every weeks | 3 |
zona zoster | 3 |
remaining patients | 3 |
part ii | 3 |
immunodeficiency virus | 3 |
coronavirus family | 3 |
psychiatric disorders | 3 |
potential adverse | 3 |
two diseases | 3 |
study cutaneous | 3 |
high dose | 3 |
infection presenting | 3 |
common search | 3 |
ablative lasers | 3 |
study conducted | 3 |
narrative review | 3 |
inanimate surfaces | 3 |
yeast infections | 3 |
pulmonary disease | 3 |
transient livedo | 3 |
treatment discontinuation | 3 |
week follow | 3 |
early transmission | 3 |
control study | 3 |
patients chilblain | 3 |
china covid | 3 |
type i | 3 |
articles published | 3 |
falls apart | 3 |
patient files | 3 |
spread rapidly | 3 |
hypercoagulable states | 3 |
three months | 3 |
confirmed sars | 3 |
specific sars | 3 |
bullous fixed | 3 |
dermatologic findings | 3 |
influenza virus | 3 |
asymptomatic carriers | 3 |
different types | 3 |
declares global | 3 |
modified aerosol | 3 |
survey study | 3 |
inhibit human | 3 |
treatment risk | 3 |
fibrin thrombi | 3 |
functional receptor | 3 |
dermatology consultation | 3 |
proper use | 3 |
botulinum toxin | 3 |
pustulosis induced | 3 |
increased incidence | 3 |
severe infection | 3 |
wearing face | 3 |
descriptive study | 3 |
asymptomatic population | 3 |
st april | 3 |
petechial purpuric | 3 |
twice daily | 3 |
dose isotretinoin | 3 |
limited data | 3 |
wuhan covid | 3 |
risk stratification | 3 |
patients underwent | 3 |
sore throat | 3 |
wore face | 3 |
therapeutic regimen | 3 |
data regarding | 3 |
medical workforce | 3 |
severe ad | 3 |
seasonal effects | 3 |
current study | 3 |
label non | 3 |
cutaneous immune | 3 |
patient care | 3 |
superficial fungal | 3 |
dermatologic disorder | 3 |
autoimmune disorders | 3 |
melanocytic nevus | 3 |
new insights | 3 |
potential role | 3 |
average age | 3 |
skin rashes | 3 |
grade fever | 3 |
immunocompromised patients | 3 |
covid toes | 3 |
within weeks | 3 |
drug administration | 3 |
personal hygiene | 3 |
emergency management | 3 |
inpatient clinics | 3 |
may highlight | 3 |
tmprss gene | 3 |
declared mask | 3 |
health status | 3 |
treatment option | 3 |
gold standard | 3 |
study group | 3 |
shoe covers | 3 |
connective tissue | 3 |
mohamad goldust | 3 |
study among | 3 |
st may | 3 |
resembling chilblains | 3 |
cancer patients | 3 |
infection rates | 3 |
consultation cases | 3 |
mask decontamination | 3 |
diagnostic criteria | 3 |
english literature | 3 |
exclusion criteria | 3 |
may predict | 3 |
first day | 3 |
higher number | 3 |
exposure time | 3 |
new therapy | 3 |
highest risk | 3 |
nervous system | 3 |
one must | 3 |
report covid | 3 |
weigh risks | 3 |
may help | 3 |
psoriasis receiving | 3 |
targeted therapies | 3 |
virus disease | 3 |
patient examination | 3 |
regarding covid | 3 |
molluscum contagiosum | 3 |
cebd coronavirus | 3 |
cells via | 3 |
complete recovery | 3 |
infantile hemangiomas | 3 |
table shows | 3 |
medical faculty | 3 |
experimental studies | 3 |
descriptive statistics | 3 |
healthcare professionals | 3 |
ad adults | 3 |
dermatological disease | 3 |
psoriasis may | 3 |
possible covid | 3 |
therapeutic agent | 3 |
given written | 3 |
sjs ten | 3 |
recall period | 3 |
erythematous scaly | 3 |
waiting area | 3 |
clinical manifestation | 3 |
healthcare worker | 3 |
adverse skin | 3 |
patient developed | 3 |
natural ventilation | 3 |
increased risks | 3 |
dermatology departments | 3 |
ongoing pandemic | 3 |
statistical relationship | 3 |
lung injury | 3 |
new sars | 3 |
diagnostic spectrum | 3 |
bullous diseases | 3 |
septic shock | 3 |
central nervous | 3 |
medical staff | 3 |
managing cutaneous | 3 |
suspected covid | 3 |
janus kinase | 3 |
previous year | 3 |
first step | 3 |
whole world | 3 |
biological agents | 3 |
slurred speech | 3 |
dermatology applications | 3 |
genital contamination | 3 |
basal layer | 3 |
severe atopic | 3 |
previous studies | 3 |
covid cases | 3 |
immunosuppressive immunomodulator | 3 |
blood count | 3 |
risk contact | 3 |
dermatology residency | 3 |
solar lentigo | 3 |
lifestyle changes | 3 |
main cause | 3 |
immunohistochemical study | 3 |
survey conducted | 3 |
near future | 3 |
ace receptor | 3 |
aesthetic practices | 3 |
british journal | 3 |
including patients | 3 |
keratosis solar | 3 |
weakly increased | 3 |
doctor therapist | 3 |
inhibitors may | 3 |
regression analysis | 3 |
significant differences | 3 |
better outcome | 3 |
regarding infection | 3 |
dimer levels | 3 |
hand dermatitis | 3 |
plasma levels | 3 |
positive covid | 3 |
treated psoriasis | 3 |
mediated diseases | 3 |
aerosolised particles | 3 |
type ii | 3 |
rash appeared | 3 |
may use | 3 |
effective therapeutic | 3 |
understanding sars | 3 |
immediate cessation | 3 |
combination therapy | 3 |
dramatically reduced | 3 |
displayed higher | 3 |
controlled phase | 3 |
additional evidence | 3 |
tight fit | 3 |
moderate risk | 3 |
pandemic dermatology | 3 |
systemic sclerosis | 3 |
human acidic | 3 |
human immunodeficiency | 3 |
american academy | 3 |
third epidemic | 3 |
histopathological study | 3 |
two months | 3 |
since march | 3 |
multiple organ | 3 |
consistent improvement | 3 |
handle reduces | 3 |
respiratory tract | 3 |
room temperature | 3 |
several types | 3 |
patients diagnosed | 3 |
strict infection | 3 |
corticosteroid treatment | 3 |
used single | 3 |
automation system | 3 |
diseases covid | 3 |
northern part | 3 |
face examination | 3 |
blood loss | 3 |
membrane pemphigoid | 3 |
atopic predisposition | 3 |
even though | 3 |
data suggest | 3 |
laboratory monitoring | 3 |
treating covid | 3 |
skin necrosis | 3 |
old male | 3 |
gene expression | 3 |
transmission dynamics | 3 |
standard face | 3 |
recombinant human | 3 |
increased mortality | 3 |
tinea pedis | 3 |
infection cutaneous | 3 |
european task | 3 |
viral disease | 3 |
cd inhibitors | 3 |
particulate air | 3 |
skin infections | 3 |
relative humidity | 3 |
hearing loss | 3 |
expert consensus | 3 |
per year | 3 |
scabies cases | 3 |
baseline airway | 3 |
lupus patients | 3 |
pandemic skin | 3 |
even higher | 3 |
underlying disease | 3 |
vascular endothelial | 3 |
increased significantly | 3 |
vascular disorders | 3 |
patient evaluation | 3 |
participants agreed | 3 |
johnson syndrome | 3 |
topical recombinant | 3 |
latin america | 3 |
young male | 2 |
zoom online | 2 |
mucosal disorders | 2 |
systemic disorder | 2 |
physical examination | 2 |
lymphocyte counts | 2 |
genital warts | 2 |
health questionnaire | 2 |
unclear whether | 2 |
tissue diseases | 2 |
overlooked dermatological | 2 |
therapeutic efficacy | 2 |
indian dermatologists | 2 |
low incidence | 2 |
renal transplant | 2 |
minimize spread | 2 |
higher scholarity | 2 |
virus origins | 2 |
istanbul university | 2 |
susceptible individuals | 2 |
increase susceptibility | 2 |
anxiety disorder | 2 |
negative consequences | 2 |
skin nail | 2 |
protective devices | 2 |
adverse reaction | 2 |
turkey italy | 2 |
added value | 2 |
pemphigus pemphigus | 2 |
highly variable | 2 |
declaration form | 2 |
generation sequencing | 2 |
immunosuppressive effect | 2 |
consider cytokine | 2 |
lung disease | 2 |
findings due | 2 |
also showed | 2 |
relationship increases | 2 |
post covid | 2 |
micrographic surgery | 2 |
zpf ri | 2 |
oropharyngeal swabs | 2 |
male patient | 2 |
patient scheduling | 2 |
present study | 2 |
recommendations may | 2 |
one week | 2 |
patients examined | 2 |
host cell | 2 |
states food | 2 |
well fitted | 2 |
discontinued taking | 2 |
current covid | 2 |
recently reported | 2 |
two cohorts | 2 |
sodium hypochlorite | 2 |
better understand | 2 |
antiviral activity | 2 |
apart like | 2 |
xdid vn | 2 |
tertiary hospital | 2 |
wtacr qj | 2 |
xerotic eczema | 2 |
days without | 2 |
temperature areas | 2 |
time rt | 2 |
eosinophilic cells | 2 |
dic due | 2 |
per i | 2 |
public holidays | 2 |
airway infections | 2 |
another study | 2 |
took place | 2 |
three weeks | 2 |
dermatology service | 2 |
changes due | 2 |
overzealous hand | 2 |
commencing rituximab | 2 |
get training | 2 |
active covid | 2 |
medication adherence | 2 |
also observed | 2 |
treatment period | 2 |
coronavirus epidemic | 2 |
maintenance immunosuppressive | 2 |
mofetil treatment | 2 |
within three | 2 |
skin inflammation | 2 |
eight questionnaires | 2 |
immunomodulator immunosuppressant | 2 |
still unknown | 2 |
nine patients | 2 |
cd therapy | 2 |
data needs | 2 |
chronic illnesses | 2 |
treating patients | 2 |
autoinflammatory disease | 2 |
flu like | 2 |
evaluated cases | 2 |
centre experience | 2 |
vs discontinuation | 2 |
dermatological manifestations | 2 |
adaptive immune | 2 |
size dermatological | 2 |
great impact | 2 |
contact procedures | 2 |
providing protection | 2 |
disease caused | 2 |
therapeutic use | 2 |
laser surgery | 2 |
certain diseases | 2 |
morbilliform exanthem | 2 |
mucosa secretions | 2 |
psychological stress | 2 |
coronavirus spike | 2 |
decrease risk | 2 |
atopic eczema | 2 |
final approval | 2 |
generating aerosols | 2 |
local ethics | 2 |
italian medium | 2 |
federico title | 2 |
qvq hu | 2 |
br cr | 2 |
online app | 2 |
recalcitrant acute | 2 |
purpuric rash | 2 |
authors contribute | 2 |
hfuvm oh | 2 |
pkt uu | 2 |
via aerosol | 2 |
resulted positive | 2 |
major consequences | 2 |
extensor surfaces | 2 |
human papillomavirus | 2 |
skin lesion | 2 |
hydroxychloroquine treatment | 2 |
uninfected patients | 2 |
exclusion groups | 2 |
must also | 2 |
surface area | 2 |
size survey | 2 |
temporal correlation | 2 |
systemic infections | 2 |
procedures maybe | 2 |
mild cough | 2 |
urticaria may | 2 |
melanoma cells | 2 |
nd generation | 2 |
problems related | 2 |
direct contact | 2 |
generalized bullous | 2 |
coronaviruses outbreaks | 2 |
taiwanese doctor | 2 |
physiological burden | 2 |
mucocutaneous blistering | 2 |
antiviral effects | 2 |
major tertiary | 2 |
heart disease | 2 |
single case | 2 |
reported cases | 2 |
generally emphasized | 2 |
dermatological consultation | 2 |
two randomized | 2 |
health measures | 2 |
cell differentiation | 2 |
older age | 2 |
proposed neurotropic | 2 |
exclude seasonal | 2 |
previous years | 2 |
week later | 2 |
national health | 2 |
reduce virus | 2 |
poor prognosis | 2 |
cutaneous lupus | 2 |
complete remission | 2 |
emergency room | 2 |
lesions appeared | 2 |
soap molecules | 2 |
clinics within | 2 |
vital organ | 2 |
potentially lethal | 2 |
symptoms related | 2 |
term treatment | 2 |
without comorbidities | 2 |
pandemic causing | 2 |
dose interval | 2 |
using chi | 2 |
skin syndrome | 2 |
immune globulin | 2 |
oral corticosteroids | 2 |
fulminans include | 2 |
knowledge prevents | 2 |
treating psoriasis | 2 |
current data | 2 |
consecutive italian | 2 |
central air | 2 |
public education | 2 |
coagulation characteristics | 2 |
immunosuppressive medications | 2 |
greater percentage | 2 |
increases linearly | 2 |
searching spectrum | 2 |
versus non | 2 |
prevent severe | 2 |
immunomodulatory medication | 2 |
gel sanitizing | 2 |
human dna | 2 |
theoretically decrease | 2 |
reactions among | 2 |
full body | 2 |
clinical images | 2 |
new antiseptic | 2 |
vesicular eruptions | 2 |
frequent use | 2 |
adult atopic | 2 |
healthcare system | 2 |
cd agents | 2 |
psoriatic systemic | 2 |
disease damage | 2 |
initial screening | 2 |
pox like | 2 |
may give | 2 |
negative results | 2 |
immunosuppressive disease | 2 |
covid date | 2 |
standard deviation | 2 |
smhto em | 2 |
chronic respiratory | 2 |
elderly people | 2 |
blood test | 2 |
home quarantine | 2 |
pustular dress | 2 |
international society | 2 |
fluctuating course | 2 |
cd therapies | 2 |
current knowledge | 2 |
wear face | 2 |
five main | 2 |
accompanying covid | 2 |
neutrophil elastase | 2 |
immunoglobulin therapy | 2 |
transition period | 2 |
child confirmed | 2 |
kjoi ea | 2 |
clinically significant | 2 |
new corona | 2 |
sars pathogenesis | 2 |
epub ahead | 2 |
nasal obstruction | 2 |
phase two | 2 |
damage index | 2 |
infected non | 2 |
pustular psoriasis | 2 |
face respirators | 2 |
remain infectious | 2 |
group members | 2 |
considered responders | 2 |
significant positive | 2 |
zoster post | 2 |
health professionals | 2 |
overall case | 2 |
mohs micrographic | 2 |
comfort zones | 2 |
fragile patients | 2 |
minimally invasive | 2 |
acral skin | 2 |
common causative | 2 |
identify skin | 2 |
decretolegge febbraio | 2 |
robustelli test | 2 |
dermatologic effects | 2 |
telephone calls | 2 |
retrospectively analyzed | 2 |
australia new | 2 |
treatment date | 2 |
nationwide analysis | 2 |
study provides | 2 |
factors associated | 2 |
yet known | 2 |
reducing mortality | 2 |
cloth mask | 2 |
phototherapeutic approach | 2 |
hypochlorite solution | 2 |
type psoriasis | 2 |
modifying therapies | 2 |
patient recovered | 2 |
inpatient consultations | 2 |
many studies | 2 |
severe risk | 2 |
preexisting chronic | 2 |
occur due | 2 |
current literature | 2 |
daniele mario | 2 |
following recovery | 2 |
second month | 2 |
erythrodermic psoriatic | 2 |
experts agreed | 2 |
new type | 2 |
mc tpnbj | 2 |
patients received | 2 |
discontinue biologics | 2 |
new onset | 2 |
box warning | 2 |
basal cell | 2 |
nasal bridge | 2 |
strong evidence | 2 |
digitate papulosquamous | 2 |
per day | 2 |
attuative del | 2 |
systematically reviewed | 2 |
east chilblain | 2 |
commonly used | 2 |
certain medications | 2 |
recent period | 2 |
phase clinical | 2 |
italian multicenter | 2 |
test positive | 2 |
repeated rh | 2 |
appeared days | 2 |
also focused | 2 |
last dose | 2 |
patients starting | 2 |
topical steroids | 2 |
prevent covid | 2 |
picture resembling | 2 |
modification vs | 2 |
outdoor areas | 2 |
potential source | 2 |
di meo | 2 |
knowledge regarding | 2 |
successful method | 2 |
molecule phosphodiesterase | 2 |
illnesses like | 2 |
authors pointed | 2 |
health authorities | 2 |
masks use | 2 |
whole body | 2 |
chronic obstructive | 2 |
exposed skin | 2 |
urinary tract | 2 |
contract sars | 2 |
avoid touching | 2 |
data analysis | 2 |
acral lesions | 2 |
effective treatment | 2 |
symptomatic treatment | 2 |
disposable sheets | 2 |
numerous facebook | 2 |
also referred | 2 |
immune checkpoint | 2 |
world economy | 2 |
australian new | 2 |
series published | 2 |
dermatological conditions | 2 |
may differ | 2 |
antibacterial products | 2 |
i response | 2 |
perspectives dress | 2 |
mitigation strategies | 2 |
protective role | 2 |
folate deficiency | 2 |
increased frequency | 2 |
causative organism | 2 |
eab i | 2 |
disease treated | 2 |
athome policy | 2 |
jak inhibitor | 2 |
questionnaire survey | 2 |
disposizioni attuative | 2 |
confidence level | 2 |
absolute pasi | 2 |
two immune | 2 |
working ports | 2 |
black box | 2 |
viral exanthem | 2 |
another approach | 2 |
phosphodiesterase inhibitor | 2 |
among elderly | 2 |
domain complexed | 2 |
nitric oxide | 2 |
checkpoint inhibitors | 2 |
medical science | 2 |
risk towards | 2 |
increased susceptibility | 2 |
data shows | 2 |
following days | 2 |
one required | 2 |
exacerbates psoriasis | 2 |
taking apremilast | 2 |
respiratory viruses | 2 |
retrospectively evaluated | 2 |
crucial role | 2 |
manifestations caused | 2 |
google forms | 2 |
anxiety disorders | 2 |
paramount importance | 2 |
italian paediatric | 2 |
versus cyclosporine | 2 |
basic fibroblast | 2 |
spike surface | 2 |
afgf application | 2 |
treated patients | 2 |
droplet transmission | 2 |
many papers | 2 |
activation syndrome | 2 |
met exclusion | 2 |
acting antiviral | 2 |
obstructive pulmonary | 2 |
satisfactory speed | 2 |
evaluated using | 2 |
serologically investigated | 2 |
disease management | 2 |
advanced melanoma | 2 |
seek medical | 2 |
dermatologists contributed | 2 |
mg group | 2 |
vesicular fluid | 2 |
surgery safely | 2 |
regression analyses | 2 |
respiratory failure | 2 |
inconveniences due | 2 |
collateral damage | 2 |
regional training | 2 |
dermatologists working | 2 |
symptoms days | 2 |
decrease adverse | 2 |
drugs including | 2 |
limited case | 2 |
malar eruption | 2 |
will judge | 2 |
significantly affected | 2 |
fold decrease | 2 |
respiratory pacemaker | 2 |
biologics discontinuation | 2 |
web spaces | 2 |
intravenous immune | 2 |
azadeh title | 2 |
human monoclonal | 2 |
patients presenting | 2 |
three patients | 2 |
devastating systemic | 2 |
autoimmune diseases | 2 |
painful skin | 2 |
blind trial | 2 |
common adverse | 2 |
adverse effect | 2 |
swabs seldom | 2 |
pcr result | 2 |
good effect | 2 |
novel corona | 2 |
like lesion | 2 |
fhy hu | 2 |
wearing surgical | 2 |
standard treatment | 2 |
sound infection | 2 |
lower levels | 2 |
eight experts | 2 |
etiologic agent | 2 |
biobadaderm registry | 2 |
first manifestations | 2 |
racial disparities | 2 |
declared indefinitely | 2 |
lesions may | 2 |
torello title | 2 |
disorders especially | 2 |
surrounding regions | 2 |
pulmonary infection | 2 |
affected parts | 2 |
active clinical | 2 |
patient management | 2 |
skin barrier | 2 |
sequencing panel | 2 |
infection among | 2 |
antipsoriatic treatments | 2 |
receiving immunosuppressive | 2 |
acute acral | 2 |
psychological distress | 2 |
masks may | 2 |
affetti da | 2 |
higher knowledge | 2 |
may change | 2 |
chilblain like | 2 |
clinical therapies | 2 |
large number | 2 |
antibiotic azithromycin | 2 |
changing paradigm | 2 |
macrophage activation | 2 |
third week | 2 |
selami aykut | 2 |
suspected cases | 2 |
severity score | 2 |
tissue factor | 2 |
dermatology patients | 2 |
hu authors | 2 |
oral retinoids | 2 |
cell depletion | 2 |
italian region | 2 |
factitious dermatitis | 2 |
critical period | 2 |
biopsy specimen | 2 |
deaths due | 2 |
washing hands | 2 |
dysmorphic disorder | 2 |
psychological status | 2 |
interval increase | 2 |
including severe | 2 |
onychomycosis medications | 2 |
currently available | 2 |
systemic drugs | 2 |
receptor binding | 2 |
widely used | 2 |
manifestations associated | 2 |
inflicted skin | 2 |
squared test | 2 |
integrated analysis | 2 |
new method | 2 |
ua gcxv | 2 |
dedicated dermatology | 2 |
reporting limited | 2 |
critical time | 2 |
may interfere | 2 |
common features | 2 |
least months | 2 |
dengue cutaneous | 2 |
studies involving | 2 |
medium size | 2 |
bothersome issues | 2 |
fulminans associated | 2 |
neurotropic mechanisms | 2 |
reach recovery | 2 |
females significantly | 2 |
personal experience | 2 |
dermatology beds | 2 |
dermatitis patients | 2 |
patient profile | 2 |
including dermatology | 2 |
procedural dermatology | 2 |
may th | 2 |
biologic medications | 2 |
panel agreed | 2 |
systematic literature | 2 |
better preparation | 2 |
highly contagious | 2 |
applications within | 2 |
review acute | 2 |
documented skin | 2 |
public wear | 2 |
serological results | 2 |
potential biological | 2 |
systemic immunomodulators | 2 |
sb rmm | 2 |
therapeutic response | 2 |
study may | 2 |
ks mq | 2 |
global crisis | 2 |
skin eruption | 2 |
fda approved | 2 |
standard version | 2 |
generated airborne | 2 |
inflammatory diseases | 2 |
family history | 2 |
cutaneus findings | 2 |
american medical | 2 |
human genome | 2 |
opportunistic infections | 2 |
venereology group | 2 |
rosea increase | 2 |
zoster neuralgia | 2 |
drug repurposing | 2 |
sexual behavior | 2 |
eczematous dermatitis | 2 |
perivascular infiltration | 2 |
medical records | 2 |
successfully treated | 2 |
outpatient department | 2 |
underlying diseases | 2 |
thrombotic findings | 2 |
manifestations appeared | 2 |
patient groups | 2 |
dermatology date | 2 |
working hours | 2 |
seldom resulted | 2 |
new dermatoses | 2 |
receptor expression | 2 |
also obtained | 2 |
vb ks | 2 |
current biologic | 2 |
syndrome following | 2 |
observation period | 2 |
ct scan | 2 |
immunomodulator therapies | 2 |
spouse partner | 2 |
first two | 2 |
teaching hospital | 2 |
omr shm | 2 |
reported literature | 2 |
systemic immunomodulating | 2 |
treatment regimens | 2 |
skin care | 2 |
upper face | 2 |
patient affected | 2 |
may include | 2 |
skin inflammatory | 2 |
significant physiological | 2 |
biologic drugs | 2 |
soap also | 2 |
support staff | 2 |
sle patients | 2 |
dermatologist attendings | 2 |
better controlling | 2 |
ten patients | 2 |
previously reported | 2 |
warmer areas | 2 |
three groups | 2 |
commonly seen | 2 |
telemedicine may | 2 |
environmental factors | 2 |
preliminary evaluation | 2 |
next scheduled | 2 |
care must | 2 |
cutaneous side | 2 |
skin tissue | 2 |
changes frequently | 2 |
high prevalence | 2 |
clinical information | 2 |
overall serious | 2 |
vice versa | 2 |
paediatric patients | 2 |
pandemic cases | 2 |
type one | 2 |
third day | 2 |
moderate symptoms | 2 |
operating room | 2 |
enhanced risk | 2 |
global coronavirus | 2 |
del decretolegge | 2 |
weeks later | 2 |
made due | 2 |
also increases | 2 |
factor anaphylotoxin | 2 |
clinical aesthetic | 2 |
host immune | 2 |
ad children | 2 |
nonfollicular pustules | 2 |
ulteriori disposizioni | 2 |
antibody response | 2 |
hand rub | 2 |
procedures involving | 2 |
scientific research | 2 |
animal models | 2 |
potential therapy | 2 |
search strategy | 2 |
icu hospitalization | 2 |
skin protection | 2 |
telephone consultations | 2 |
expert recommendations | 2 |
identify clinical | 2 |
also used | 2 |
essential material | 2 |
published contemporarily | 2 |
chronic comorbidities | 2 |
generation antihistamines | 2 |
covid toe | 2 |
public hospitals | 2 |
com trends | 2 |
chronic arthritis | 2 |
diagnostic tool | 2 |
also reported | 2 |
including biologics | 2 |
recommendations based | 2 |
multicenter survey | 2 |
cytokine storms | 2 |
therapy may | 2 |
ablative co | 2 |
pulmonary involvement | 2 |
doxycycline doses | 2 |
may suggest | 2 |
simplex chronicus | 2 |
reactions related | 2 |
autoimmune mucocutaneous | 2 |
fatality rates | 2 |
known whether | 2 |
purpuric eruption | 2 |
italian society | 2 |
possible correlation | 2 |
continuation vs | 2 |
face interviews | 2 |
fungal infections | 2 |
best practices | 2 |
presenting symptom | 2 |
measures including | 2 |
based products | 2 |
infectious material | 2 |
physician nurse | 2 |
care hospital | 2 |
usually associated | 2 |
much beyond | 2 |
lesions described | 2 |
studies performed | 2 |
isolated igg | 2 |
rare autoimmune | 2 |
basement membrane | 2 |
reduce covid | 2 |
became ubiquitous | 2 |
procedures generating | 2 |
pressure sore | 2 |
patients date | 2 |
disease may | 2 |
postherpetic neuralgia | 2 |
articles assigned | 2 |
drugs may | 2 |
clinical diagnosis | 2 |
supplementary table | 2 |
diffuse alveolar | 2 |
kji bbn | 2 |
home isolation | 2 |
lgg gya | 2 |
human herpes | 2 |
unwashed hands | 2 |
ace receptors | 2 |
physical distance | 2 |
younger ages | 2 |
average complexity | 2 |
using zoom | 2 |
southern italy | 2 |
less fears | 2 |
inflammatory properties | 2 |
mask wearing | 2 |
recently published | 2 |
viral infectious | 2 |
therapeutic approach | 2 |
declaration date | 2 |
cutaneous covid | 2 |
stainless steel | 2 |
urgent visits | 2 |
vesicular eruption | 2 |
outpatient departments | 2 |
protect healthcare | 2 |
liver disease | 2 |
survey among | 2 |
pandemic key | 2 |
bprnq wx | 2 |
patients needed | 2 |
sclerosis treated | 2 |
practice changes | 2 |
corresponding period | 2 |
inconsistent behavior | 2 |
inflammatory drugs | 2 |
za zhi | 2 |
pazienti affetti | 2 |
comorbidities like | 2 |
considered statistically | 2 |
urgent dermatological | 2 |
first week | 2 |
may contribute | 2 |
made based | 2 |
tract infection | 2 |
poorer prognosis | 2 |
hypercoagulable state | 2 |
elective cases | 2 |
draw attention | 2 |
stat signaling | 2 |
control cytokine | 2 |
platelet count | 2 |
comprehensive review | 2 |
allow us | 2 |
cutaneous vasculitis | 2 |
patients experience | 2 |
critical care | 2 |
repeated application | 2 |
beard hair | 2 |
supportive care | 2 |
caution commencing | 2 |
many concerns | 2 |
emergency medicine | 2 |
covid cutaneous | 2 |
dissecting hematomas | 2 |
organ damage | 2 |
human transmission | 2 |
starting medications | 2 |
bonferroni correction | 2 |
stable curve | 2 |
patient health | 2 |
phase three | 2 |
longer duration | 2 |
home policy | 2 |
coefficient regression | 2 |
ace protein | 2 |
viral particles | 2 |
analysis epub | 2 |
moral dilemma | 2 |
requested dermatology | 2 |
significant changes | 2 |
current viral | 2 |
treatment considerations | 2 |
surface protein | 2 |
biocidal agents | 2 |
finding status | 2 |
severe clinical | 2 |
dermatology visits | 2 |
ircss san | 2 |
reverse transcription | 2 |
video conferencing | 2 |
skin condition | 2 |
strict standard | 2 |
three studies | 2 |
well known | 2 |
possible sources | 2 |
occurs due | 2 |
randomized study | 2 |
treating multiple | 2 |
chloride patch | 2 |
old healthy | 2 |
may decrease | 2 |
clinical perspectives | 2 |
body rash | 2 |
low particulate | 2 |
working protocols | 2 |
first seen | 2 |
diminished without | 2 |
day period | 2 |
one basis | 2 |
ocrelizumab versus | 2 |
prevents biologics | 2 |
potential risk | 2 |
old age | 2 |
one may | 2 |
hospital visits | 2 |
eye protection | 2 |
aesthetic procedure | 2 |
organ systems | 2 |
several skin | 2 |
wear surgical | 2 |
membrane zone | 2 |
melanoma cell | 2 |
igm iga | 2 |
storm syndromes | 2 |
pi wcv | 2 |
maculopapular rashes | 2 |
vesicular rashes | 2 |
employing rituximab | 2 |
pandemic covid | 2 |
review article | 2 |
covid became | 2 |
including interleukin | 2 |
computed tomography | 2 |
scholarity level | 2 |
vaginal fluids | 2 |
full agreement | 2 |
evidence based | 2 |
presenting sign | 2 |
cutaneous diseases | 2 |
analyzed articles | 2 |
cd antigen | 2 |
elective patients | 2 |
diseases like | 2 |
residential address | 2 |
confirmatory testing | 2 |
eczema followed | 2 |
coagulation score | 2 |
categories showed | 2 |
randomised trial | 2 |
virus infectivity | 2 |
required urgent | 2 |
recent reports | 2 |
aesthetic medicine | 2 |
transmission via | 2 |
specific advice | 2 |
skin tag | 2 |
resume outpatient | 2 |
dermatological surgeries | 2 |
lower limbs | 2 |
genomic characterisation | 2 |
important factor | 2 |
pediatric dermatoses | 2 |
caffeic acid | 2 |
systemic therapies | 2 |
dermatologic patients | 2 |
goldust https | 2 |
avoiding touching | 2 |
biological hazards | 2 |
increased airway | 2 |
disease ward | 2 |
fetal pulmonary | 2 |
treatment treatment | 2 |
theoretical increased | 2 |
oral isotretinoin | 2 |
i pazienti | 2 |
cases acral | 2 |
cause severe | 2 |
pruritic lesions | 2 |
possible association | 2 |
different countries | 2 |
since covid | 2 |
adverse dermatologic | 2 |
reported three | 2 |
critical intensive | 2 |
medical colleges | 2 |
procedure chairs | 2 |
distinctive skin | 2 |
dose intravenous | 2 |
included patients | 2 |
contribute equally | 2 |
oral tablet | 2 |
influenza pneumonia | 2 |
research hospital | 2 |
showed cutaneous | 2 |
infection presented | 2 |
months earlier | 2 |
mycological confirmation | 2 |
body surface | 2 |
practices may | 2 |
pathogenic mechanism | 2 |
may theoretically | 2 |
multidisciplinary care | 2 |
conventional treatments | 2 |
tqlg bac | 2 |
eight patients | 2 |
blood vessels | 2 |
vascular occlusion | 2 |
helsinki declaration | 2 |
six patients | 2 |
late onset | 2 |
minimize risk | 2 |
common cause | 2 |
challenging case | 2 |
available literature | 2 |
current scenario | 2 |
nosocomial transmission | 2 |
mostly reported | 2 |
collagen vascular | 2 |
dhh patient | 2 |
cytokine levels | 2 |
patients coming | 2 |
questionnaire study | 2 |
remaining ten | 2 |
pandemic since | 2 |
commonly reported | 2 |
linearly according | 2 |
ii level | 2 |
armed forces | 2 |
adequately powered | 2 |
mucosal surfaces | 2 |
bee glue | 2 |
mask use | 2 |
smoke evacuation | 2 |
viral pandemics | 2 |
frequent washing | 2 |
kinase inhibitors | 2 |
study effect | 2 |
virus membrane | 2 |
may represent | 2 |
intravenous immunoglobulins | 2 |
will make | 2 |
therapeutics toxic | 2 |
viruses via | 2 |
viral spike | 2 |
petechial rash | 2 |
effective measure | 2 |
secukinumab mg | 2 |
pandemic clinical | 2 |
much attention | 2 |
emerging viruses | 2 |
eczema among | 2 |
psoriasis severity | 2 |
study reported | 2 |
new covid | 2 |
international flights | 2 |
carefully monitored | 2 |
low number | 2 |
propensity score | 2 |
infection disease | 2 |
increased stress | 2 |
mohammad reza | 2 |
promotes il | 2 |
psoriasis covid | 2 |
professional face | 2 |
italian red | 2 |
tertiary center | 2 |
action covid | 2 |
negative serological | 2 |
sufficient evidence | 2 |
elective aesthetic | 2 |
retrospective studies | 2 |
patients due | 2 |
patients based | 2 |
severe adult | 2 |
lesions diminished | 2 |
popular ones | 2 |
committee approval | 2 |
oxr es | 2 |
outbreak evaluation | 2 |
wp vh | 2 |
olfactory epithelium | 2 |
symptoms may | 2 |
significantly lower | 2 |
healthy women | 2 |
rapidly spreading | 2 |
coagulation factors | 2 |
eczematous disorders | 2 |
varying according | 2 |
data suggests | 2 |
essential outpatient | 2 |
psoriasis flare | 2 |
kgph lr | 2 |
hemorrhagic complications | 2 |
inpatient care | 2 |
protection provided | 2 |
codes entered | 2 |
study real | 2 |
diseases presented | 2 |
appropriate precautions | 2 |
patient sars | 2 |
cutaneous melanoma | 2 |
many varieties | 2 |
widely recognized | 2 |
human cells | 2 |
clinicopathological confirmation | 2 |
study clinical | 2 |
risk assessment | 2 |
respiratory epithelium | 2 |
emergency dermatological | 2 |
pernio affects | 2 |
nonpruritic maculopapular | 2 |
therapies key | 2 |
medications reported | 2 |
posterity will | 2 |
suspected sars | 2 |
platelet levels | 2 |
shedding light | 2 |
systemic involvement | 2 |
achieving pasi | 2 |
blood cell | 2 |
xk dt | 2 |
causing increased | 2 |
experienced mild | 2 |
exhaled nitric | 2 |
hbcu cm | 2 |
two authors | 2 |
area systemic | 2 |
positive rt | 2 |
recommendation may | 2 |
air filtration | 2 |
specific patient | 2 |
cd antigens | 2 |
paolo title | 2 |
chronic skin | 2 |
education campaigns | 2 |
rheumatoid arthritis | 2 |
previous examination | 2 |
also included | 2 |
viral contamination | 2 |
fatal disease | 2 |
emergency cases | 2 |
first screening | 2 |
pcr covid | 2 |
many factors | 2 |
purpuric eruptions | 2 |
dependent il | 2 |
statistically significance | 2 |
article published | 2 |
coronavirus sars | 2 |
skin symptoms | 2 |
maculopapular eruptions | 2 |
therapy biologics | 2 |
benzalkonium chloride | 2 |
showing pityriasis | 2 |
ana positivity | 2 |
sexual partners | 2 |
secondary covid | 2 |
arthritis treated | 2 |
eight weeks | 2 |
oral nd | 2 |
immunomodulatory effect | 2 |
death due | 2 |
erbakan university | 2 |
treating asthma | 2 |
erythematous lesions | 2 |
includes hepatic | 2 |
nasal vestibule | 2 |
ii pneumocytes | 2 |
facial hair | 2 |
decreased production | 2 |
skin problems | 2 |
patients per | 2 |
started reopening | 2 |
italy experience | 2 |
cr kj | 2 |
laboratory study | 2 |
dgs oih | 2 |
rash diminished | 2 |
varying degrees | 2 |
last days | 2 |
laser procedures | 2 |
uva phototherapy | 2 |
standard operating | 2 |
definite treatment | 2 |
idiopathic pruritus | 2 |
infezione da | 2 |
human testis | 2 |
symptoms following | 2 |
potential covid | 2 |
quickly spread | 2 |
operating procedures | 2 |
lesser irritant | 2 |
european guidelines | 2 |
hearing patients | 2 |
procedures like | 2 |
many areas | 2 |
advocate caution | 2 |
candida infections | 2 |
prognostic factors | 2 |
clinical predictors | 2 |
certain procedures | 2 |
also considered | 2 |
many skin | 2 |
reported among | 2 |
new diagnoses | 2 |
potential new | 2 |
care settings | 2 |
literature knowledge | 2 |
among medical | 2 |
glass opacity | 2 |
washington state | 2 |
nq jwgr | 2 |
nasal surface | 2 |
viral shedding | 2 |
name novel | 2 |
wai man | 2 |
vademecum per | 2 |
raising concerns | 2 |
respiratory infection | 2 |
induced itch | 2 |
necmettin erbakan | 2 |
participants declared | 2 |
significantly inhibit | 2 |
coronavirus outbreak | 2 |
will allow | 2 |
one case | 2 |
prevention measures | 2 |
among hcw | 2 |
three days | 2 |
smoke evacuators | 2 |
level hospital | 2 |
call visits | 2 |
causing covid | 2 |
type two | 2 |
igg serology | 2 |
multivariate logistic | 2 |
previously healthy | 2 |
jx waah | 2 |
concerns regarding | 2 |
causing severe | 2 |
like india | 2 |
antiseptic strategies | 2 |
may offer | 2 |
perspective key | 2 |
use hydroxychloroquine | 2 |
research projects | 2 |
adverse cutaneous | 2 |
raas blockers | 2 |
appropriate use | 2 |
relative frequency | 2 |
scar formation | 2 |
chronic dermatologic | 2 |
autoimmune blistering | 2 |
inr instead | 2 |
first three | 2 |
fzj ciif | 2 |
pacemaker neurons | 2 |
blood serum | 2 |
natural remedies | 2 |
per week | 2 |
significant impact | 2 |
transplanted recipients | 2 |
skin cancers | 2 |
perceived stress | 2 |
nasal congestion | 2 |
different parts | 2 |
eczema area | 2 |
usable recommendation | 2 |
conventional systemic | 2 |
analysis showed | 2 |
band ultraviolet | 2 |
significant values | 2 |
patients achieved | 2 |
virus targeting | 2 |
severe illness | 2 |
procedure room | 2 |
skin reaction | 2 |
proinflammatory cytokine | 2 |
higher incidence | 2 |
infection date | 2 |
may appear | 2 |
patients achieving | 2 |
cases presenting | 2 |
lichen simplex | 2 |
among young | 2 |
social isolation | 2 |
responders declared | 2 |
complement factor | 2 |
therapy covid | 2 |
assessing infection | 2 |
chest pain | 2 |
obese patients | 2 |
study showing | 2 |
transmitted covid | 2 |
another viral | 2 |
chemical peels | 2 |
retrospective review | 2 |
injury covid | 2 |
severe skin | 2 |
guidelines detailing | 2 |
suspected onychomycosis | 2 |
isolated iga | 2 |
acral ischemia | 2 |
receiving systemic | 2 |
perception varying | 2 |
new oral | 2 |
immunomodulator agents | 2 |
i opmcn | 2 |
renal transplanted | 2 |
became pandemic | 2 |
early treated | 2 |
pasi compared | 2 |
heart rate | 2 |
adequate supply | 2 |
generating medical | 2 |
lessons learned | 2 |
patients key | 2 |
real life | 2 |
immunomodulating therapy | 2 |
increased health | 2 |
performing dermoscopy | 2 |
immunosuppressive agents | 2 |
speckled pattern | 2 |
peripheral blood | 2 |
literature dermatologic | 2 |
retinoic acid | 2 |
purpura may | 2 |
dengue fever | 2 |
face elastomeric | 2 |
mg weekly | 2 |
ad solo | 2 |
common infections | 2 |
red zone | 2 |
well established | 2 |
leukocytoclastic vasculitis | 2 |
pcr within | 2 |
cases cutaneous | 2 |
lesion severity | 2 |
immunosuppressant use | 2 |
mortality rate | 2 |
diagnoses made | 2 |
patients among | 2 |
global cases | 2 |
recovered completely | 2 |
old previously | 2 |
airborne contaminants | 2 |
positive correlation | 2 |
therapy date | 2 |
surgical procedures | 2 |
affected almost | 2 |
scoring systems | 2 |
morbilliform rash | 2 |
filtration efficiency | 2 |
first weeks | 2 |
skin irritation | 2 |
direct acting | 2 |
conventional therapies | 2 |
rapid test | 2 |
patients tested | 2 |
i fully | 2 |
final analysis | 2 |
depression scale | 2 |
avoid infection | 2 |
dermatological finding | 2 |
care costs | 2 |
medical procedures | 2 |
countries like | 2 |
immunosuppressive targeted | 2 |
still debated | 2 |
surface mucosa | 2 |
multicenter study | 2 |
distal extremities | 2 |
care worker | 2 |
efficiency particulate | 2 |
medical advice | 2 |
serine protease | 2 |
condition may | 2 |
patients covid | 2 |
oral phosphodiesterase | 2 |
states dermatology | 2 |
small molecule | 2 |
procedure chair | 2 |
js aw | 2 |
kidney transplant | 2 |
monitor psoriatic | 2 |
virus interaction | 2 |
infection may | 2 |
like findings | 2 |
undergoing biological | 2 |
donning doffing | 2 |
procedures may | 2 |
hospital anxiety | 2 |
minimum airflow | 2 |
hu nan | 2 |
pathological findings | 2 |
undergoing biologics | 2 |
used cloth | 2 |
may trigger | 2 |
body dysmorphic | 2 |
potential target | 2 |
high infection | 2 |
dry gangrene | 2 |
prompt use | 2 |
psoriasis area | 2 |
using antiseptics | 2 |
nasal mucosal | 2 |
transmitted disease | 2 |
increased need | 2 |
frequently used | 2 |
early diagnosis | 2 |
median number | 2 |
serum level | 2 |
secondary care | 2 |
disease onset | 2 |
advice guideline | 2 |
sexual contact | 2 |
stabilized period | 2 |
preliminary data | 2 |
higher compared | 2 |
less likely | 2 |
patients applied | 2 |
liberty ad | 2 |
liver enzymes | 2 |
may become | 2 |
first presentation | 2 |
transmission routes | 2 |
human ace | 2 |
high doses | 2 |
used several | 2 |
palpable petechiae | 2 |
environmental resistance | 2 |
hand cream | 2 |
entry depends | 2 |
inperson visits | 2 |
rapid advice | 2 |
digit ischemia | 2 |
commonly involved | 2 |
facebook groups | 2 |
italy date | 2 |
vaginal swabs | 2 |
olfactory function | 2 |
better understanding | 2 |